Swiss Malaria Group
Founded in 2007 as an informal network, the Swiss Malaria Group (SMG) has undergone organisational development leading to a formalized multi-stakeholder group with a strategic focus on raising awareness about malaria and the comparative advantage of Switzerland to defeat the disease. Organised as an association, with an Executive Secretariat hosted by Medicus Mundi Switzerland, the 13 organisations help accelerating malaria elimination, through innovative control measures, knowledge and financial flows.
Health systems strengthening
- Organisational Development and Networking: Making use of synergies to join forces
- Advocacy (within Switzerland and collaborative with international organisations): Recognizing Switzerland as a leader and mobilizing resources for fighting malaria
- Public relations: Increasing sensitisation and awareness
- Technical information sharing: Sharing best practices and dissemination of technical information across different stakeholders
- Creation of the Executive Secretary hosted by Medicus Mundi Switzerland
- Formalisation of SMG as an association (inaugural meeting on 22 April 2015)
- Development of a shared vision and strategy (2014-2019)
- Launch of SMG webpage (www.swissmalariagroup.ch)
- Organisation of a parliamentary study tour to Tanzania in April 2015
- Realisation of technical exchange day in Basel (22 April 2015)
- Realisation of an event at World Malaria Day (25th April 2015), Basel Natural History Museum
- Other Swiss Non-profit Organisation
Despite great progress over the past 15 years, malaria remains a major global public health issue, with an estimated 3.3 billion people in 97 countries still being at risk of the disease and 214 million cases occurring every year.
Publicly and privately funded partnerships have enabled Switzerland to assume a pioneering and internationally recognized leading role in research and development efforts for new medicines and diagnostic products. Swiss-based organisations are among the principal actors in the global fight against malaria. The group underpins Switzerland’s role and competence in research, innovation and application in defeating malaria.
Joint commitment of Swiss stakeholders in knowledge exchange and fundraising contributes to accelerating malaria control and elimination at a critical time. The group has a potential to foster multisectorial approaches and to promote better integration of tools and products into health systems. The group has a potential to reinforce a focus on malaria elimination in the era of the Sustainable Development Goals.
To sustain and increase Swiss innovation and commitment to malaria elimination.
Beneficiaries are people in malaria endemic countries all over the world who benefit from increased investments into malaria control and elimination efforts.
Further beneficiaries are organisations in Switzerland whose activities rely on malaria-related funding and which benefit from technical exchanges.
Outcome 1: Organisational development: collaboration of all members and financial sustainability of SMG ensured
Outcome 2: Advocacy: Malaria is on the agenda of official and corporate Switzerland and advocacy is aligned with the international malaria community
Outcome 3: Public awareness in Switzerland is created
Outcome 4: Best practices are shared, technical information is disseminated
Output 1: The SMG strategy is refined in alignment with the global elimination agenda and the 2030 agenda for sustainable development.
Output 2: A code of conduct is established.
Output 3: Membership is increased by three new members.
Output 4: Two key advocacy events and /or key meetings have taken place to position Swiss leadership in defeating malaria.
Output 5: Swiss business leaders against malaria informative event (e.g. roundtable) and follow-up has taken place.
Output 6: Key messages are defined and communicated to target audience.
Output 7: A communication concept is elaborated and in use.
Output 8: One key event to raise public awareness is organised by SMG every 2nd year.
Output 9: SMG value chain visualised and communicated.
Output 10: One technical exchange is carried out per year
Results from previous phases:
|Directorate/federal office responsible||
World Health Organization, Roll Back Malaria
|Coordination with other projects and actors||
Novartis Pharma, Novartis Foundation, Syngenta, Biovision, Medicus Mundi Switzerland, Swiss Red Cross, Solidarmed, Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), Foundation for Innovative New Diagnostics, Swiss Tropical and Public Health, Centre Hospitalier Universitaire Vaudois
|Budget||Current phase Swiss budget CHF 630'000 Swiss disbursement to date CHF 510'000|
|Project phases||Phase 99 01.01.2020 - 31.12.2025 (Active) Phase 1 01.07.2014 - 31.12.2019 (Current phase)|